Pharmaceutical companies will make billions of dollars a year from the boron dose of the corona vaccine
Web Desk / Reuters - Market experts and healthcare investors say pharmaceutical companies will make billions of dollars from the booster dose of Pfizer Bio-N Tech and the Modern Code-19 vaccine.That the vaccine will be available in the coming years.Pharmaceutical companies will compete with the flu vaccine in terms of revenue.Which generates 6 6 billion annually.
Vaccine Companies
For the past several months, the vaccine companies have been saying that those who have received full doses of the vaccine will need a booster dose to keep their immune system strong against the new variants of Corona.
Many countries around the world have decided to give vaccine booster doses to their elderly citizens.Those with weakened immune systems to protect them from the rapidly spreading delta variant.These countries include Chile, Germany and Israel.
United States Food & Drug Administration
The U.S. Food and Drug Administration on Thursday approved a booster diet for people with weakened immune systems.
The revenue of vaccine companies can be estimated from the fact that Pfizer and its German partners Bio-N Tech and Moderna have struck deals worth more than 60 billion in 2021 and 2022 to supply vaccines.The deals include the first two doses of the vaccine, as well as billions of dollars worth of booster doses.
Pfizer & Bio-N Tech
Analysts say that in 2023, Pfizer Bioven Tech will receive 6.6 billion, mostly from its booster doses, while Moderna will receive 7.6 billion.Once more vaccine companies enter the field.Their annual revenue will drop to 5 billion or more.
Vaccine companies say experiments on people who have been given full doses of the vaccine have shown a decrease in antibody levels after about six months.On the other hand, with the advent of fast-spreading delta variants.It has become necessary to give them a booster dose to increase the amount of antibodies.
Because of the differences in vaccine strengths of different companies.It is difficult to say when a booster dose may be needed.
Some scientists have also questioned whether there is enough data to conclude that booster diets are needed, especially among young people and healthy people.
WHO
The World Health Organization (WHO) has asked governments not to give booster doses until more people get the initial dose of the vaccine.
Market experts say that if the general public were to be vaccinated against coronavirus as usual.It would be similar to the flu vaccine business.Which has a market of more than 600 million.The money is divided into four US companies.
Flu Cost Vaccine in US
The cost of the flu vaccine is determined by half of the country's population in developed countries.Experts say that the price of the booster dose of Code-19 will be determined in the same way.
Flu vaccines cost between 18 and 25 per dose, according to official U.S. government figures, while prices could rise by four to five percent this year.
Licensing experts say Pfizer and Moderna's booster food prices could remain high until vaccines from other companies compete.
The Pfizer vaccine currently costs 19.50 in the United States.While new deals have increased the price by 25%.
Morning Star analyst Damien Conover says many companies are not in the market right now.It is estimated that other vaccine companies will enter the market within a year.After which booster doses and their prices will be determined.
Vimal Devon, an analyst at Mizuho Securities, says at least five companies are expected to enter the vaccine market.
Managing Director of Healthcare
Baijan Salehzada, managing director of healthcare investment firm Newmed Capital, says it is likely that the US government will continue to pay companies to keep the cost of the vaccine higher by stopping the spread of COD-19 to make it more effective.Keep trying. And this can continue as long as the spread of the virus is not effectively reduced.
0 Comments